Semaglutide, which is approved for managing T2D and obesity, works by enhancing insulin secretion, thereby reducing glucagon release, lowering blood glucose levels, and suppressing appetite, leading to weight loss [34]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.